The Recall Desk

Manufacturer

SUN PHARMACEUTICAL INDUSTRIES INC

85 recalls in our database name SUN PHARMACEUTICAL INDUSTRIES INC as the manufacturing or recalling firm.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

1–25 of 85

  • LowFDA (Drugs)·D-0654-2026·2026-07-08

    Fexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities

    SUN PHARMACEUTICAL INDUSTRIES INC is recalling Fexofenadine Hydrochloride Tablets, USP 180 mg distributed nationwide because the product failed impurities and degradation specifications. The recall affects approximately 9,048 bottles distributed across the United States.

    Product
    Fexofenadine Hydrochloride Tablets, USP 180 mg, Antihistamine, 150 Tablets per bottle, Distributed by: Ohm Laboratories, Inc., New Brunswick, NJ 08901. NDC 66336-561-30
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-0628-2026·2026-07-01

    Perampanel Prescription Tablets Recalled for Labeling Mix-up

    Sun Pharmaceutical is recalling Perampanel 6 mg tablets due to labeling mix-up where 10 mg tablets were found in bottles labeled as 6 mg. Patients should verify their bottles with their pharmacy or physician.

    Product
    PERAMPANEL — PERAMPANEL (PERAMPANEL)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0607-2026·2026-06-17

    BUDESONIDE (BUDESONIDE)

    Pending LLM rewrite. Source: FDA_DRUG D-0607-2026.

    Product
    BUDESONIDE — BUDESONIDE (BUDESONIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0580-2026·2026-06-17

    DOXORUBICIN HYDROCHLORIDE (DOXORUBICIN HYDROCHLORIDE)

    Pending LLM rewrite. Source: FDA_DRUG D-0580-2026.

    Product
    DOXORUBICIN HYDROCHLORIDE — DOXORUBICIN HYDROCHLORIDE (DOXORUBICIN HYDROCHLORIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0477-2026·2026-04-22

    FLUOCINONIDE (FLUOCINONIDE)

    Pending LLM rewrite. Source: FDA_DRUG D-0477-2026.

    Product
    FLUOCINONIDE — FLUOCINONIDE (FLUOCINONIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0475-2026·2026-04-22

    FLUOCINONIDE (FLUOCINONIDE)

    Pending LLM rewrite. Source: FDA_DRUG D-0475-2026.

    Product
    FLUOCINONIDE — FLUOCINONIDE (FLUOCINONIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0476-2026·2026-04-22

    FLUOCINONIDE (FLUOCINONIDE)

    Pending LLM rewrite. Source: FDA_DRUG D-0476-2026.

    Product
    FLUOCINONIDE — FLUOCINONIDE (FLUOCINONIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0342-2026·2026-02-11

    DICLOFENAC SODIUM (DICLOFENAC SODIUM)

    Pending LLM rewrite. Source: FDA_DRUG D-0342-2026.

    Product
    DICLOFENAC SODIUM — DICLOFENAC SODIUM (DICLOFENAC SODIUM)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0256-2026·2026-01-21

    FLUOCINOLONE ACETONIDE (FLUOCINOLONE ACETONIDE)

    Pending LLM rewrite. Source: FDA_DRUG D-0256-2026.

    Product
    FLUOCINOLONE ACETONIDE — FLUOCINOLONE ACETONIDE (FLUOCINOLONE ACETONIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0257-2026·2026-01-21

    CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE)

    Pending LLM rewrite. Source: FDA_DRUG D-0257-2026.

    Product
    CLINDAMYCIN PHOSPHATE — CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0150-2026·2025-11-05

    LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)

    Pending LLM rewrite. Source: FDA_DRUG D-0150-2026.

    Product
    LISDEXAMFETAMINE DIMESYLATE — LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0145-2026·2025-11-05

    LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)

    Pending LLM rewrite. Source: FDA_DRUG D-0145-2026.

    Product
    LISDEXAMFETAMINE DIMESYLATE — LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0148-2026·2025-11-05

    LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)

    Pending LLM rewrite. Source: FDA_DRUG D-0148-2026.

    Product
    LISDEXAMFETAMINE DIMESYLATE — LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0147-2026·2025-11-05

    LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)

    Pending LLM rewrite. Source: FDA_DRUG D-0147-2026.

    Product
    LISDEXAMFETAMINE DIMESYLATE — LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0144-2026·2025-11-05

    LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)

    Pending LLM rewrite. Source: FDA_DRUG D-0144-2026.

    Product
    LISDEXAMFETAMINE DIMESYLATE — LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0146-2026·2025-11-05

    LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)

    Pending LLM rewrite. Source: FDA_DRUG D-0146-2026.

    Product
    LISDEXAMFETAMINE DIMESYLATE — LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0149-2026·2025-11-05

    LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)

    Pending LLM rewrite. Source: FDA_DRUG D-0149-2026.

    Product
    LISDEXAMFETAMINE DIMESYLATE — LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0658-2025·2025-09-24

    KIT FOR THE PREPARATION OF TECHNETIUM TC99M MERTIATIDE (BETIATIDE)

    Pending LLM rewrite. Source: FDA_DRUG D-0658-2025.

    Product
    KIT FOR THE PREPARATION OF TECHNETIUM TC99M MERTIATIDE — KIT FOR THE PREPARATION OF TECHNETIUM TC99M MERTIATIDE (BETIATIDE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0574-2025·2025-08-13

    SPIRONOLACTONE (SPIRONOLACTONE)

    Pending LLM rewrite. Source: FDA_DRUG D-0574-2025.

    Product
    SPIRONOLACTONE — SPIRONOLACTONE (SPIRONOLACTONE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • Severity pendingFDA (Drugs)·D-0516-2025·2025-07-23

    LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)

    Pending LLM rewrite. Source: FDA_DRUG D-0516-2025.

    Product
    LISDEXAMFETAMINE DIMESYLATE — LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • LowFDA (Drugs)·D-0312-2025·2025-04-16

    Gabapentin Capsules 400 mg Recalled for Cross Contamination

    Sun Pharmaceutical Industries Inc. is recalling Gabapentin Capsules 400 mg due to cross contamination. The recall affects 852 bottles distributed nationwide.

    Product
    GABAPENTIN — GABAPENTIN (GABAPENTIN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • LowFDA (Drugs)·D-0311-2025·2025-04-16

    Gabapentin Capsules Recalled for Cross Contamination

    Sun Pharmaceutical Industries is recalling Gabapentin Capsules, USP 300 mg, due to cross contamination. The recall affects approximately 12,876 bottles distributed nationwide.

    Product
    GABAPENTIN — GABAPENTIN (GABAPENTIN)
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-0249-2025·2025-03-12

    Morphine Sulfate Tablets Recalled Over Failed Dissolution Specifications

    Sun Pharmaceutical is recalling Morphine Sulfate Extended-Release 100 mg tablets (lot AD16615) because they fail dissolution specifications, potentially resulting in unpredictable drug delivery.

    Product
    MORPHINE SULFATE — MORPHINE SULFATE (MORPHINE SULFATE)
    Category
    Drug
    Distribution
    Distributed nationwide